SomaLogic has revolutionized aptamer-based proteomics.
Our pioneering platform provides more coverage of the proteome than any other technology. With more coverage comes better insights, smarter decisions, improved outcomes, better healthcare. SomaLogic is an industry leader in proteomics, adding new analytes and developing innovative ways to advance your work every single day.
Discover how the world’s leading life science and pharmaceutical research organizations are transforming their discovery and validation pipelines with our groundbreaking proteomic technologies.
Real-time health information that enables health systems to make better decisions and improve outcomes across their populations.
Analyze and visualize all your studies in one clear, concise, and convenient view on the SomaLogic Life Sciences Portal. Combine study tracking with the power of statistical analysis and data visualization, and access our full menu of analytes.
We built the first and only platform that can simultaneously measure 7,000 proteins across a wide range of concentrations. Now we’re translating those measurements into key clinical indicators of health status and risk.
7,000 proteins per sample
Top tier facilities
CLIA-licensed ultra high-throughput lab
Proteomics and clinical metrics from 55 μL of blood
20 years of innovation, >500 patents
Do you know the clues that proteogenomics reveals?
Pairing large-scale protein measurements with next-generation sequencing and finding correlations via pQTLs can help researchers better connect the dots among genetic variations, disease, and druggable targets.
For insights across multiple diseases
Accelerate your biomarker discovery with sensitive detection of 7,000 proteins from a 55-µL sample.
Measure 7,000 proteins at once and find patterns no one knew to look for.
Discover multiple cardiovascular indicators from a 55-µL plasma sample.
The SomaScan® Assay could advise patients on lifestyle changes to help prevent the onset of type 2 Diabetes.
Non-invasive research that predicts NASH with serum protein biomarkers.
Get a high-throughput, multiplex proteomics solution that focuses on the complexity of neurological diseases.
Advancing rare disease research with powerful protein profiling and offering new insights into biomarker discovery.
WATCH ON DEMAND
Researchers show how they’ve found hidden causal links between disease and genetic variations using proteomic analysis to identify relevant pQTLs
Carlos Cruchaga, PhD
B. Burton & R.M. Morris III Professor of Psychiatry
McDonnell Genome Institute
Washington University School of Medicine in St. Louis
The first multi-tissue study yielding hundreds of novel pQTLs. This data will be instrumental to identify the functional gene from GWAS signals, identify novel biological protein-protein interactions, and identify novel potential biomarkers and drug targets for complex traits.
Benjamin Sun, PhD, MB, BChir
Royal Free Hospital
Dr. Sun’s team at the University of Cambridge used the SomaScan Assay to develop a pQTL atlas of human plasma. They quantified 3,622 plasma proteins in 3,301 healthy participants and identified 1,927 pQTLs, 88 of which overlapped with disease susceptibility loci.